Retatrutide trial reference

What the trial studied

Retatrutide, also called LY3437943 or reta, remains investigational as of November 6, 2026. It activates GIP, GLP-1, and glucagon receptors. TRIUMPH-1 randomized 2,339 adults with obesity without diabetes to once-weekly subcutaneous trial injections or placebo for 80 weeks.

The published treatment-regimen analysis reported average weight reduction of 25.0% in the highest-dose group versus 3.9% with placebo. This analysis addresses outcomes under assignment to treatment, including treatment interruptions. A percentage quoted under a different analysis can answer a different question. Trial averages do not predict an individual's response.

Cadence belongs to the study

Once weekly describes the research schedule. There is no FDA-approved retatrutide product or prescribing label. The study's injectable preparation does not validate a seller's powder, vial, oral product, or nasal product. The catalog's injection form describes the studied route.

Gastrointestinal events were the most common adverse events. An 80-week study cannot establish lifelong safety or what happens after stopping. Published results do not supply a personal starting amount or escalation schedule.

Keep a useful record

For a clinician discussion, record the reason for the discussion, diagnoses, other medicines, and any product already used, including its source. Include dates and symptoms rather than inferring a cause from a weight chart.

If participating in research, retain the trial identifier, study-team contact, assigned formulation if known, administration dates, and the team's written instructions. Preserve any treatment blinding. Changes belong with the study team. A tracker records events and instructions; it does not turn a trial into a treatment plan.